65th ASH Annual Meeting & Exposition: 906. Outcomes Research – Myeloid Malignancies: Symptom Burden and Supportive Therapies

Symposia: Outcomes Research—Myeloid Malignancies Oral and Poster Abstracts
Oral

Research, Clinical Research, health outcomes research, Diseases, real-world evidence, registries, Myeloid Malignancies, Study Population, Human

Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)

Moderators:

Noha Sharafeldin, MD, PhD, University of Alabama at Birmingham and Nandita Khera, MD, Mayo Clinic

Disclosures:

Khera: Incyte: Honoraria.

2:45 PM

913

Multi-Site Randomized Trial of Inpatient Palliative Care for Hospitalized Patients Undergoing Hematopoietic Stem Cell Transplantation

Areej El-Jawahri, MD¹, Thomas W LeBlanc, MD², Alison Kavanaugh³^*, Jason Webb, MD⁴^*, James Fausto⁵^*, Lara Traeger³^*, Joseph Greer, PhD³^*, Vicki Jackson, MD³^*, Nora Horick⁶^*, Zachariah Defilipp, MD⁷, Yi-Bin Chen, MD, MS³, Stephanie J. Lee⁸ and Jennifer Temel³^*

¹Massachusetts General Hospital, Allston, MA
²Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC
³Massachusetts General Hospital, Boston, MA
⁴Oregon Health and Sciences University, Portland, OR
⁵Fred Hutchinson Cancer Research Center, Seattle, WA
⁶Massachusetts General Hospital, Boston
⁷Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA
⁸Fred Hutchinson Cancer Center, Seattle, WA

3:00 PM

914

Utilization Patterns and Outcomes from Iron Chelation in Elderly Patients with Low-Risk Myelodysplastic Syndrome

Diego Adrianzen Herrera, MD¹, Andrew Sparks, MS²^*, Rohit Singh, MD³^*, Katherine Giorgio, MPH⁴^*, Pamela Lutsey, PhD, MPH⁴^* and Neil Zakai³

¹Larner College of Medicine at the University of Vermont, Burlington, VT
²Biomedical Statistics Research Core at the University of Vermont, Burlington, VT
³Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT
⁴University of Minnesota School of Public Health, Minneapolis, MN

3:15 PM

915

Long-Term Evaluation of Luspatercept in Erythropoiesis‑Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

Valeria Santini¹, Rami S. Komrokji, MD², Guillermo Garcia-Manero, MD³, Rena Buckstein, MD, FRCPC⁴, Esther Natalie Oliva, MD⁵, Karen L. Keeperman⁶^*, Shelonitda Rose⁶^*, Ana Carolina Giuseppi⁶^*, Valerie Vilmont⁷^*, Yinzhi Lai⁶^*, Dimana Miteva⁷^*, Barkha Aggarwal⁶^*, Uwe Platzbecker, MD⁸, Pierre Fenaux, MD, PhD⁹ and Amer M. Zeidan, MBBS, MHS¹⁰

¹MDS Unit, Hematology, University of Florence, AOUC, Florence, Italy
²Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
³University of Texas MD Anderson Cancer Center, Houston, TX
⁴Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
⁵U.O.C. Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio di Calabria, Italy
⁶Bristol Myers Squibb, Princeton, NJ
⁷Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
⁸Department of Hematology, Cell Hematology and Hemostaseology, Leipzig University Hospital, Leipzig, Germany
⁹Hôpital Saint-Louis, Université Paris 7, Paris, France
¹⁰Department of Internal Medicine, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT

3:30 PM

916

Real-World Impact of Luspatercept on Patients with Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions and with Prior Exposure to Erythropoietin-Stimulating Agents: A United States Healthcare Claims Database Study

Kashyap Patel¹^*, Kirollos S. Hanna²^*, Enrico Zanardo, PhD³^*, Ali McBride, PharmD⁴, Victoria Barghout⁵^*, Rui Song⁶^*, Lynn Huynh, DrPH, MBA, MPH⁷^*, Derek Tang⁴^*, Mihran Yenikomshian⁶^* and Leslie A. Andritsos⁸

¹Carolina Blood and Cancer Care Associates, Rock Hill, SC
²Minnesota Oncology, Minneapolis, MN
³Analysis Group, Denver, CO
⁴Bristol Myers Squibb, Princeton, NJ
⁵VEB Healthcare, Morristown, NJ
⁶Analysis Group, Boston, MA
⁷Analysis Group, Inc., Boston, MA
⁸University of New Mexico, Albuquerque, NM

3:45 PM

917

Prospective Symptom Burden Analysis in 784 Patients with Myeloproliferative Neoplasms: High Burden Correlates with Inflammatory/Genetic Biomarkers and Reduced Survival

Alisa Poullet, MD¹^*, Lambert Busque, MD^2,3,4, Shireen Sirhan, MD, FRCP^3,5, Robert Delage, MD, MSc^3,6, Ghislain Cournoyer, MD^3,7, Ines Chamakhi, MD^3,8, Danielle Talbot, MD^3,9^*, Luigina Mollica, MD, PhD^2,3,4^*, Daniele Marceau, MD^3,10, Vincent Ethier, MD, BSc^3,11, Pierre Desjardins, MD^3,12^*, Harold J. Olney, MD^3,4,13, Michaël Harnois³^* and Natasha Szuber, MD, MSc^2,3,4

¹Department of Internal Medicine, University of Montreal Hospital Center, Montréal, QC, Canada
²Department of Hematology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada
³Quebec CML-MPN Research Group, Montreal, QC, Canada
⁴University of Montreal, Montreal, QC, Canada
⁵Segal Cancer Center, Jewish General Hospital, Montreal, QC, Canada
⁶Integrated Cancer Center, CHU de Québec, Laval University, Quebec, QC, Canada
⁷Hemato-oncology, St-Jérôme Hospital, Saint-Jerome, Canada
⁸Hemato-oncology, Hôpital du Sacré-Cœur de Montréal, Montreal, QC, Canada
⁹Hemato-oncology, Cité-de-la-Santé Hospital, Laval, QC, Canada
¹⁰Hemato-oncology, Hôtel-Dieu de Lévis, Quebec, QC, Canada
¹¹Sherbrooke University Hospital Center (CHUS), Sherbrooke University, Sherbrooke, QC, Canada
¹²Hemato-oncology, Charles-Lemoyne Hospital, Sherbrooke University, Sherbrooke, Canada
¹³Department of Hematology, University of Montreal Hospital Center, Montreal, QC, Canada

4:00 PM

918

Patient-Reported Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD Mutation Receiving Quizartinib Vs. Standard Chemotherapy: Results from the Quantum-First Trial

Esther Natalie Oliva, MD^1,2, Sudhir Unni³^*, Francesco Cottone⁴^*, Rohan Vashi⁵^*, Xiaocong Li⁶^*, Jorge Cortes, MD⁷ and Mikkael A. Sekeres, MD⁸

¹U.O.C. Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy
²U.O.C. Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Reggio Calabria, Italy
³Daiichi Sankyo, Inc, Basking Ridge, NJ
⁴Daiichi Sankyo Italia S.p.A, Roma, Italy
⁵Daiichi Sankyo, Inc, Basking Ridge
⁶OPEN Health Evidence & Access, Bethesda
⁷Georgia Cancer Center, Augusta University, Augusta, GA
⁸Sylvester Cancer Center, University of Miami, Miami, FL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

906.O1.6 906. Outcomes Research – Myeloid Malignancies: Symptom Burden and Supportive Therapies